A novel approach for body weight management using a bacterial surfactin lipopeptide. (June 2018)

• Record Type: Journal Article
• Authors: Meena, Khem Raj; Parmar, Ashwarya; Sharma, Abhishek; Kanwar, Shamsher S.
• Is Part Of: Obesity medicine. Volume 10(2018)
• Page Start: 24
• Page End: 28
• Publication Date: 2018-06
• Subjects: B. subtilis -- Lipopeptide -- Murine pre-adipocyte cells -- Obesity -- Porcine pancreatic lipase -- Surfactin; Obesity -- Periodicals; Obesity; Obesity; Periodicals; Periodicals; 616.398005
• DOI: 10.1016/j.obmed.2018.05.003
• Languages: English
• ISSNs: 2451-8476

Abstract

Abstract: Aim: To explore the antiobesity activity of the Surfactin lipopeptide (LP) obtained from B. subtilis KLP2015 strain (Accession number KT459335). Methods: Cytotoxicity of bacterial Surfactin towards a murine pre-adipocytic 3T3-L1 cell line was determined by MTT assay. The inhibition of porcine pancreatic lipase (PPL) and Steapsin by Surfactin lipopeptide was also detected by a colorimetric assay. Results: The 50% inhibitory concentration (IC50 ) value of Surfactin for 3T3-L1 cells was found to be ∼15 μg/ml in the MTT assay. Surfactin lipopeptide of B. subtilis KLP2015 reduced the activity of Steapsin and PPL by 51.37% and 67.20%, respectively after 60 min of reaction time. The fat content in the murine 3T3-L1 cells gradually decreased by 31.09 and 36.85% after treatment with 30 μg/ml and 150 μg/ml of Surfactin, respectively as the 3T3-L1 cells treated with Surfactin shed considerable amount of oil droplets. In the Surfactin-PPL docking study, the Surfactin molecule interacted via hydrogen bonding with Ser53, His75 and Asp83 residues of PPL. Conclusion: Surfactin LP of B. subtilis KLP2015 strain is an ideal molecule that may be developed as a candidate drug for the treatment of obesity in future. Highlights: This is the first study of Surfactin lipopeptide attempted to control/manage the obesity using an animal cell system. The IC50 value for 3T3-L1 cell line was found to be ∼15 μg/ml in MTT assay. SLP was found to be a potent inhibitor of both Steapsin and PPL. Fat content of 3T3-L1 preadipocyte cells reduced by 31.09% and 36.85% at LP concentration of 30 and 150 μg/ml, respectively. LP-treated 3T3-L1 cells shed fat, and Surfactin interacted via H-bonding with Ser53, His75 and Asp83 of PPL in docking study.